{"id":21843,"date":"2025-01-02T09:00:42","date_gmt":"2025-01-02T09:00:42","guid":{"rendered":"https:\/\/makingpharmaindustry.it\/non-categorizzato\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/"},"modified":"2025-01-10T11:19:58","modified_gmt":"2025-01-10T11:19:58","slug":"innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici","status":"publish","type":"post","link":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/","title":{"rendered":"Regulatory innovations and implementation strategies to ensure sterility in pharmaceutical processes"},"content":{"rendered":"<p data-pm-slice=\"1 1 []\">The <strong>update of Annex 1 of the European GMPs<\/strong> represents a crucial step for the pharmaceutical industry, aimed at improving sterility management in production processes. The new version emphasizes a paradigm shift towards &#8220;<strong>Quality by Design<\/strong>&#8221; (QbD), where process design and control take center stage, moving beyond the traditional concept of &#8220;Quality by Testing&#8221;. This article delves into two key chapters of Annex 1: <strong>Quality Control<\/strong> (Chapter 10) and <strong>Aseptic Process Simulation<\/strong> (APS, Chapter 9), highlighting their practical implications and implementation challenges.<\/p>\n<h2>Quality Control in the New Annex 1<\/h2>\n<p><strong>Chapter 10 of Annex<\/strong> 1 redefines quality control expectations, emphasizing the importance of scientific knowledge and the <strong>Contamination Control Strategy (CCS)<\/strong>. Technical specifications must be closely tied to the risks identified during the process, and contamination monitoring is essential to ensure product safety. Key requirements include:<\/p>\n<ol start=\"1\" data-spread=\"true\">\n<li><strong>Pre-sterilization bioburden: <\/strong>Each batch must be tested for bioburden immediately before sterile filtration or terminal sterilization. Limits must be aligned with the efficiency of the sterilization process, with a maximum guideline value of 10 CFU\/100 ml for TAMC (Total Aerobic Microbial Count).\n<div class=\"mb-2 flex gap-3 empty:hidden -ml-2\"><\/div>\n<\/li>\n<li><strong>Sterility Testing<\/strong><strong>: <\/strong>Despite the limited statistical significance, the sterility test remains crucial for confirming the effectiveness of control measures. It must be conducted in a Class A environment, with strict monitoring of operating conditions to avoid false positives.\n<div class=\"mb-2 flex gap-3 empty:hidden -ml-2\"><\/div>\n<\/li>\n<li><strong>Rapid Microbiological Methods:<\/strong> The adoption of automated and rapid methods is strongly encouraged to enhance data reliability and integrity, reduce the risk of human error, and expedite batch release.<\/li>\n<\/ol>\n<h2>Aseptic Process Simulation (APS): a cornerstone of the CCS<\/h2>\n<p>Il Chapter 9 si concentra sulla Simulazione dei Processi Asettici (APS), un pilastro per dimostrare la conformit\u00e0 continua nei processi di produzione sterile. La nuova versione dell\u2019Annex introduce importanti cambiamenti rispetto al passato:<\/p>\n<ul data-spread=\"true\">\n<li><strong>Risk Assessment and Worst-Case Conditions:<\/strong> The APS must faithfully replicate the production process, including critical interventions and worst-case operating conditions. For example, for lyophilized products, it is essential to simulate the maximum duration of the loading and unloading phases.<\/li>\n<li>\n<div class=\"flex max-w-full flex-col flex-grow\">\n<div class=\"min-h-8 text-message flex w-full flex-col items-end gap-2 whitespace-normal break-words text-start [.text-message+&amp;]:mt-5\" dir=\"auto\" data-message-author-role=\"assistant\" data-message-id=\"50a676e4-fcb8-4064-a7ac-2bb88d2e6c15\" data-message-model-slug=\"gpt-4o\">\n<div class=\"flex w-full flex-col gap-1 empty:hidden first:pt-[3px]\">\n<div class=\"markdown prose w-full break-words dark:prose-invert dark\">\n<p><strong>Frequency and Revalidation Criteria:<\/strong> The APS must be performed at least twice a year for each aseptic process and each filling line, covering all work shifts. Additionally, an extraordinary APS is required in case of significant changes to operational practices or equipment.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/li>\n<li><strong><strong>Zero Tolerance <\/strong><\/strong><strong>for Contaminated Units:<\/strong> Any contaminated unit results in the failure of the APS, requiring a thorough investigation to determine the root causes and the implementation of appropriate corrective measures.\n<div class=\"mb-2 flex gap-3 empty:hidden -ml-2\"><\/div>\n<\/li>\n<\/ul>\n<h2>Training and documentation: pillars of implementation<\/h2>\n<p>Staff <strong>training is a fundamental element for the success of APS and quality control<\/strong>. Operators must be qualified through regular APS sessions, and any contamination during APS is grounds for exclusion from activities until requalification is achieved. Documentation is equally crucial: every intervention, monitoring activity, and result must be accurately recorded to ensure <strong>transparency and traceability<\/strong>.<\/p>\n<p><strong>Challenges and practical solutions<br \/>\n<\/strong><\/p>\n<p>The implementation of the new requirements can pose a significant challenge, especially for companies with less advanced infrastructures. Among the main difficulties:<\/p>\n<ol>\n<li><strong>Equipment adaptation:<\/strong> The need for Class A environments and automated systems requires substantial investments.<\/li>\n<li><strong>Staff training:<\/strong> Ensuring that all operators understand and adhere to the new standards demands intensive and ongoing training programs.<\/li>\n<li><strong>Validation of new methods:<\/strong> The introduction of rapid and automated methods must be accompanied by rigorous validation to demonstrate their equivalence with traditional methods.<\/li>\n<\/ol>\n<p>Practical solutions include using gap analysis to identify critical areas for improvement, adopting innovative technologies, and fostering a collaborative approach among different business functions.<\/p>\n<p>The new Annex 1 represents a unique <strong>opportunity for the pharmaceutical industry to elevate quality and sterility standards<\/strong>. While implementation poses significant challenges, a structured approach based on the CCS, supported by continuous training and advanced technologies, can ensure compliance and enhance product safety for patients. The key to success lies in the ability to integrate scientific knowledge and best operational practices at every stage of the manufacturing process.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Annex 1 of the European GMP has recently been updated, introducing new requirements for quality control and aseptic process simulations (APS). This article examines the main regulatory updates, focusing on implementation challenges and practical solutions to ensure compliance with the most stringent sterility standards. It will discuss the concepts of &#8220;Quality by Design&#8221; and Contamination Control Strategy (CCS), as well as the importance of training and the use of rapid and automated methods for microbiological control.<\/p>\n","protected":false},"author":32,"featured_media":21814,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[810,845],"tags":[],"class_list":{"0":"post-21843","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-gmp-en","8":"category-quality"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ANNEX1 EU GMP to ensure sterility in pharmaceutical processes<\/title>\n<meta name=\"description\" content=\"Quality Control and Simulation of Aseptic Processes: The New Annex 1 Guidelines to Ensure Sterility in Pharma Production\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ANNEX1 EU GMP to ensure sterility in pharmaceutical processes\" \/>\n<meta property=\"og:description\" content=\"Quality Control and Simulation of Aseptic Processes: The New Annex 1 Guidelines to Ensure Sterility in Pharma Production\" \/>\n<meta property=\"og:url\" content=\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/\" \/>\n<meta property=\"og:site_name\" content=\"MakingPharmaIndustry\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-02T09:00:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-10T11:19:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/01\/AdobeStock_1015681121-scaled.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1435\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Valentina Parrella\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Valentina Parrella\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/\"},\"author\":{\"name\":\"Valentina Parrella\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/5e59d6ee887eb3eafd7887d214ff1a09\"},\"headline\":\"Regulatory innovations and implementation strategies to ensure sterility in pharmaceutical processes\",\"datePublished\":\"2025-01-02T09:00:42+00:00\",\"dateModified\":\"2025-01-10T11:19:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/\"},\"wordCount\":638,\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/01\/AdobeStock_1015681121-scaled.jpeg\",\"articleSection\":[\"GMP\",\"Quality &amp; Validation\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/\",\"name\":\"ANNEX1 EU GMP to ensure sterility in pharmaceutical processes\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/01\/AdobeStock_1015681121-scaled.jpeg\",\"datePublished\":\"2025-01-02T09:00:42+00:00\",\"dateModified\":\"2025-01-10T11:19:58+00:00\",\"author\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/5e59d6ee887eb3eafd7887d214ff1a09\"},\"description\":\"Quality Control and Simulation of Aseptic Processes: The New Annex 1 Guidelines to Ensure Sterility in Pharma Production\",\"breadcrumb\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/#primaryimage\",\"url\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/01\/AdobeStock_1015681121-scaled.jpeg\",\"contentUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/01\/AdobeStock_1015681121-scaled.jpeg\",\"width\":2560,\"height\":1435},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/makingpharmaindustry.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Regulatory innovations and implementation strategies to ensure sterility in pharmaceutical processes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/\",\"name\":\"MakingPharmaIndustry\",\"description\":\"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/5e59d6ee887eb3eafd7887d214ff1a09\",\"name\":\"Valentina Parrella\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"caption\":\"Valentina Parrella\"},\"url\":\"https:\/\/makingpharmaindustry.it\/en\/author\/valentina-parrella\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ANNEX1 EU GMP to ensure sterility in pharmaceutical processes","description":"Quality Control and Simulation of Aseptic Processes: The New Annex 1 Guidelines to Ensure Sterility in Pharma Production","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/","og_locale":"en_US","og_type":"article","og_title":"ANNEX1 EU GMP to ensure sterility in pharmaceutical processes","og_description":"Quality Control and Simulation of Aseptic Processes: The New Annex 1 Guidelines to Ensure Sterility in Pharma Production","og_url":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/","og_site_name":"MakingPharmaIndustry","article_published_time":"2025-01-02T09:00:42+00:00","article_modified_time":"2025-01-10T11:19:58+00:00","og_image":[{"width":2560,"height":1435,"url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/01\/AdobeStock_1015681121-scaled.jpeg","type":"image\/jpeg"}],"author":"Valentina Parrella","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Valentina Parrella","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/#article","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/"},"author":{"name":"Valentina Parrella","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/5e59d6ee887eb3eafd7887d214ff1a09"},"headline":"Regulatory innovations and implementation strategies to ensure sterility in pharmaceutical processes","datePublished":"2025-01-02T09:00:42+00:00","dateModified":"2025-01-10T11:19:58+00:00","mainEntityOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/"},"wordCount":638,"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/01\/AdobeStock_1015681121-scaled.jpeg","articleSection":["GMP","Quality &amp; Validation"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/","url":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/","name":"ANNEX1 EU GMP to ensure sterility in pharmaceutical processes","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/#primaryimage"},"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/01\/AdobeStock_1015681121-scaled.jpeg","datePublished":"2025-01-02T09:00:42+00:00","dateModified":"2025-01-10T11:19:58+00:00","author":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/5e59d6ee887eb3eafd7887d214ff1a09"},"description":"Quality Control and Simulation of Aseptic Processes: The New Annex 1 Guidelines to Ensure Sterility in Pharma Production","breadcrumb":{"@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/#primaryimage","url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/01\/AdobeStock_1015681121-scaled.jpeg","contentUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/01\/AdobeStock_1015681121-scaled.jpeg","width":2560,"height":1435},{"@type":"BreadcrumbList","@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/gmp-en\/innovazioni-regolatorie-e-strategie-di-implementazione-per-garantire-la-sterilita-nei-processi-farmaceutici\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/makingpharmaindustry.it\/en\/"},{"@type":"ListItem","position":2,"name":"Regulatory innovations and implementation strategies to ensure sterility in pharmaceutical processes"}]},{"@type":"WebSite","@id":"https:\/\/makingpharmaindustry.it\/en\/#website","url":"https:\/\/makingpharmaindustry.it\/en\/","name":"MakingPharmaIndustry","description":"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/5e59d6ee887eb3eafd7887d214ff1a09","name":"Valentina Parrella","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","caption":"Valentina Parrella"},"url":"https:\/\/makingpharmaindustry.it\/en\/author\/valentina-parrella\/"}]}},"_links":{"self":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/21843","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/comments?post=21843"}],"version-history":[{"count":3,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/21843\/revisions"}],"predecessor-version":[{"id":21846,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/21843\/revisions\/21846"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media\/21814"}],"wp:attachment":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media?parent=21843"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/categories?post=21843"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/tags?post=21843"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}